Ronald Hurst, M.D.
Request An Appointment Call Dr. Ronald Hurst
888.600.5600
Marina Del Rey Hospital - Dr. Ronald Hurst
Dr. Hurst is a General Surgery, Cancer Care (Oncology), Vascular Surgery and General Medicine provider at Marina Del Rey Hospital, whose clinical interests include Sarcoma, Breast Cancer, Colon Cancer, Melanoma and Rectal Cancer. Board certified by the American Board of Surgery, Dr. Hurst is a graduate of Creighton University School of Medicine and he spent his residency at Charles R. Drew University of Medicine and Science Medical Center. Dr. Hurst is a member of the American College of Surgeons and a Healthgrades recognized doctor.

Insurance Accepted

  • Aetna
  • Blue Cross / Blue Shield
  • Cigna
  • Coventry Health Care
  • HealthNet
  • Medicare
  • MultiPlan
  • United Healthcare
  • WellPoint

Languages Spoken

  • English
  • Spanish
Medical Degree

Creighton University School Of Medicine

Internship(s)

Martin Luther King-Drew Harbor Medical Center, Los Angeles, CA

Residency(ies)

Martin Luther King/Drew UCLA Med Center

Fellowship(s)

National Institute Hlth/Natl Cancer Insti


Honors and Awards

  • Healthgrades Honor Roll
  • American College of Surgeons
    American College of Surgeons
  • American Society of Breast Surgeons
    American Society of Breast Surgeons
  • Society of Surgical Oncology
    Society of Surgical Oncology
  • American Society of Clinical Oncology
    American Society of Clinical Oncology
  • National Medical Association
    National Medical Association
  • Los Angeles Surgical Society
    Los Angeles Surgical Society

    • Laparoscopic Continuous Hyperthermic Peritoneal Perfusion

      Eugene Change, M.D., H. Richard Alexander, M.D., Steven K. Libutti, M.D., Ronald Hurst, M.D., Suoping Zhai, Ph.D., William D. Figg, M.D., David L. Bartlett, M.D.: “Laparoscopic Continuous Hyperthermic Peritoneal Perfusion”. Journal of the American College of Surgeons. Aug 2001;193(2):225-9.

    • Brain Metastasis After Immunotherapy in Patients with Metastatic Melanoma or Renal Cell Cancer: Is Craniotomy Indicated?

      R. Hurst, M.D., D. White, J Heiss, M.D. D. Lee, M.D. S. A. Rosenberg, M.D. D. Schwartzentruber, M.D.: “Brain Metastasis After Immunotherapy in Patients with Metastatic Melanoma or Renal Cell Cancer: Is Craniotomy Indicated?” Journal of Immunotherapy vol 22 No.4, 1999.

    • Patterns of Relapse and Response to Retreatment in Patients with Metastatic Melanoma or Renal Cell Carcinoma who Responded to Interleukin-2 based Immunotherapy

      D. S. Lee, M.D., D. White, R. Hurst. M.D., S.A. Rosenberg, M.D., J. Yang, M.D.: “Patterns of Relapse and Response to Retreatment in Patients with Metastatic Melanoma or Renal Cell Carcinoma who Responded to Interleukin-2 based Immunotherapy”. Journal of The American College of Surgeons.

    • Prospective Randomized Evaluation of the Prophylactic Use of Low-dose Dopamine in Cancer Patients Receiving Interleukin-2

      J. N. Cormier, M.D., R. Hurst, M.D., J. Vasselli, M. D., D. Lee, M.D., C. Kim, M.D., M. McKee, M.D., D. Venzon, D. White, F. Marincola, M.D., S. Rosenberg, M.D.: “Prospective Randomized Evaluation of the Prophylactic Use of Low-dose Dopamine in Cancer Patients Receiving Interleukin-2”. Journal of Immunology March, 1997.

    • Rectal Carcinoma: Are We Making A Difference?

      R. Hurst, M.D., G. D. Wilmoth, M.D., M. Stamos, M.D.: “Rectal Carcinoma: Are We Making A Difference?” Am Surg-1996 Oct; 62(10): 806-10.